**Title:** Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients

Dr. Baykal 16721 Tulek baykaltulek@yahoo.com MD ¹, Dr. Habibe 16722 Koylu
dr.habibe1209@hotmail.com MD ², Dr. Fikret 16723 Kanat fkanat@selcuk.edu.tr MD ¹, Dr. Ugur 16724
Arslan uarslan@selcuk.edu.tr MD ³ and Dr. Faruk 16725 Ozer fozer@farabi hastanesi.com.tr MD ⁴, ¹
Pulmonary Diseases, Selcuk University, Selcuklu Faculty of Medicine, Konya, Turkey ; ² Pulmonary Diseases, Konya University, Meram Faculty of Medicine, Konya, Turkey ; ³ Microbiology, Selcuk University,
Selcuklu Faculty of Medicine, Konya, Turkey and ⁴ Pulmonary Diseases, Farabi Hospital, Konya, Turkey .

**Body:** The basic uses of C reactive protein (CRP) and procalcitonin (PCT) in the clinical practise is in the
diagnosis and follow-up of infectious disease. The fact that CRP already achieves high levels in cases with
lung cancer, however, limits its diagnostic specificity. PCT may be an important marker in the differential
diagnosis of febrile lung cancer patients with high CRP levels. Our objective in this study was to determine
the levels of CRP and PCT in patients with newly diagnosed non-infectious non-small cell lung cancer
(NSCLC) and to relate these results to patient and disease characteristics. Serum CRP and PCT levels
were measured in 79 histopathologically proved NSCLC patients and 20 healthy controls. Results were
compared with demographic and clinical variables in patients with NSCLC. Serum CRP concentrations were
significantly higher in NSCLC patients compared to the control group (7.79 (3.36 – 26.10) mg/dl vs. 38.30
(7.79 – 185) mg/dl; p<0.001). There were no significant difference between two groups in PCT levels
(p>0.05). A mild, positive correlation was found between CRP level and tumor diameter. When comparing
CRP levels in the lung cancer patients grouped according to age, sex, smoking status, clinical TNM staging
and performance status (PS), the only significant difference found was that according to PS score. High
serum CRP levels in noninfectious NSCLC patients are mainly related to PS status and tumour size. Adding
serum PCT measurement in these patients may contribute to exclude infections in patients with NSCLC.